在快速采用后评估囊性纤维化调节器疗法的长期有效性:双重方法研究
Pedro Miranda Afonso1, Grace C Zhou2,3, Weiji Su3,4
1Erasmus MC, Department of Epidemiology and Biostatistics, Rotterdam, Zuid-Holland, Netherlands; p.mirandaafonso@erasmusmc.nl.
Annals of the American Thoracic Society
|September 8, 2025
概括
伊瓦卡夫托尔治疗改善了囊性纤维化 (CF) 患者的肺功能. 在人体内和人体间的分析显示出类似的有效性,尽管对年轻人建议谨慎.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 伊瓦卡夫托彻底改变了囊性纤维化 (CF) 护理,但长期的真实世界有效性数据很难获得.
- 较新的调节器是标准的护理,使得与未经治疗的组进行比较变得复杂.
研究的目的:
- 评估 ivacaftor 在CF中的长期肺功能保护.
- 为了比较主体内和主体间的分析,以评估现实世界的药物或药物的有效性.
主要方法:
- 使用美国CF基金会患者登记 (2003-2016) 的回顾性队列研究.
- 评估了ivacaftor对1秒内预测的百分比强迫呼气量 (ppFEV1) 的影响,使用对象内部和对象之间的分析.
- 倾向性得分与560名 ivacaftor 治疗的 G551D 变异患者与2800名未治疗的 F508del 同性合体个体相匹配.
主要成果:
- 在接受治疗的个体中,ivacaftor提高了ppFEV1的4.54-6.53%.
- 与儿童相比,成年人肺功能下降的速度较慢.
- 接受IVACAFTOR治疗的患者的衰退比未接受治疗的同行小 (0.36-0.64%的差异).
结论:
- 伊瓦卡夫托在所有年龄段改善了ppFEV1,达到临床试验效益的约50%.
- 建议在未来的CFTR调节器研究中进行主体内分析,并考虑启动偏差.
- 年轻个体的发育变化在解释治疗前后数据时需要谨慎.
相关概念视频
Cystic Fibrosis: Management
477
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
477
Cystic Fibrosis: Pathogenesis
730
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
730
COPD: Management Using Bronchodilators and Corticosteroids
741
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
741
Antiasthma Drugs: Leukotriene Modifiers
1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.8K
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
Pulmonary Tuberculosis V
543
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
543


